PLPPR4

Across TCGA pan-cancer cohorts, PLPPR4 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PLPPR4 data layer compared with 21 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher PLPPR4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PLPPR4 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SCLC show a favorable association.

LIHC, UCEC, and SCLC are the cancer types where PLPPR4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.226	0.773	.008	12	view →
UCEC	DFS	Median	All	0.951	0.611	.005	12	view →
SCLC	OS	Median	All	0.670	0.221	.026	10	view →
LUAD	DFS	Median	IV	0.671	0.893	.019	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PLPPR4–LIHC (OS)

Open the LIHC breakdown →